GlobalDatas pharmaceuticals report, Taxotere (Gastric Cancer) - Analysis and Forecasts to 2020 provides Taxotere sales estimates for US, EU5 and Japan . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Taxotere including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Taxotere including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2002-2020 for Taxotere in each of the US, EU5 and Japan markets 

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

List of Tables

Table 1: Gastric Cancer, Global, Estimated Incidences and Mortality, 2008-2030 5
Table 2: Gastric Cancer, Global, Estimated Market Sales ($bn),2009-2020 7
Table 3: Approval and Expiry of Taxotere 14
Table 4: Drug Risk Benefit Score of Taxotere 16
Table 5: Gastric Cancer, Annual Dosage of Taxotere 18
Table 6: Gastric Cancer, Global, Estimated Sales of Taxotere($m), 20022016 19
Table 7: Gastric Cancer, the US, Estimated Sales of Taxotere($m), 20062014 20
Table 8: Gastric Cancer, the UK, Estimated Sales of Taxotere($m), 20062014 21
Table 9: Gastric Cancer, France, Estimated Sales of Taxotere($m), 20062014 21
Table 10: Gastric Cancer, Germany, Estimated Sales of Taxotere($m), 20062014 22
Table 11: Gastric Cancer, Italy, Estimated Sales of Taxotere($m), 20062014 22
Table 12: Gastric Cancer, Spain, Estimated Sales of Taxotere($m), 20062014 23
Table 13: Gastric Cancer, Japan, Estimated Sales of Taxotere($m), 20022016 23

List of Figures

Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption, the US,1976-2006 6
Figure 4: Gastric Cancer, Global, Estimated Market Sales ($m),2009-2020 7
Figure 5: Oncology, Global, Estimated Incidence(million),2008-2030 8
Figure 6: Gastric Cancer, Global, Estimated Incidence (million),2008-2030 9
Figure 7: Broad Classification of Gastric Cancer in the US and EU-5 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Phase III results, Taxotere + Cisplatin + Fluorouracil 14
Figure 13: Taxotere Efficacy 15
Figure 14: Drug Model Diagram of Taxotere in the US and EU-5 17
Figure 15: Drug Model Diagram of Taxotere in Japan 18
Figure 16: Gastric Cancer, Global, Estimated Sales of Taxotere($m), 20022016 19
Figure 17: Gastric Cancer, the US, Estimated Sales of Taxotere($m), 20062014 20
Figure 18: Gastric Cancer, the UK, Estimated Sales of Taxotere($m), 20062014 20
Figure 19: Gastric Cancer, France, Estimated Sales of Taxotere($m), 20062014 21
Figure 20: Gastric Cancer, Germany, Estimated Sales of Taxotere($m), 20062014 21
Figure 21: Gastric Cancer, Italy, Estimated Sales of Taxotere($m), 20062014 22
Figure 22: Gastric Cancer, Spain, Estimated Sales of Taxotere($m), 20062014 22
Figure 23: Gastric Cancer, Japan, Estimated Sales of Taxotere($m), 20022016 23